Digifluidic completed the A+ round of financing of nearly 100 million yuan
Release date:2022/09/29
  • Share to:


Zhuhai Digifluidic Bio-tech Co., Ltd. ("Digifluidic" or "Digifluidic" for short)  recently announced the completion of nearly 100 million yuan A round of financing. This round of financing is led by Qudao Assets investment, convergence Nova fund, Wuhan Mingde Biotechnology Co., Ltd. with investment. This round of financing will be mainly used to rapidly increase the market share of the company's products in the field of in vitro diagnostics, accelerate the company's R&D and production line process in the precision medical service industry, strengthen the domestic and overseas distribution of products, and consolidate the favorable market position of Diqi Biotics in the domestic fully automatic POCT products.


Founded in 2018, Digifluidic is a scientific and technological innovative enterprise with independent innovation ability as the core driving force. Based on Digital Microfluidic technology, the company built a life science analysis and operation platform. Relying on the strong research platform of the University of Macau and its Key Laboratory of Microelectronics and the regional advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, Digifluidic gathers cutting-edge talents from various disciplines and industries to carry out research and development according to the development trend of research frontiers. Digital microfluidic technology is applied to the chip products of Diqibio to achieve precise separation, movement, mixing and other operations of the reaction liquid up to the order of picoliter by manipulating the electric field. Moreover, high-precision temperature control module, magnetic bead control module and reagent lyophilization, drying, liquid storage and other technical modules are integrated on the chip. Enabling complex life science applications to be implemented on a single microfluidic chip. Based on the accumulation of technology on microfluidic chip platform, Diqi Biological products are applied in many fields, such as in vitro diagnostic nucleic acid analysis, cancer cell culture drug sensitivity analysis, protein expression vector construction, single cell analysis and so on.


Image: Digital Microfluidic 

Introduction to Investment Organization

Guangzhou Qudao Asset Management Co., Ltd. is a professional equity investment fund manager for the medical industry. The fund investors include a number of listed companies in the medical industry and government guidance funds, etc. The industrial resources cover in depth in vitro diagnosis, new drug research and development, CXO, life science tools, etc. Qudao Asset team has rich industry experience and resource network, through industrial chain integration, strategic mergers and acquisitions, equity investment and other ways, to provide strategic resources and capital market support for enterprises.

Convergence New Star Fund: A fund jointly established by Guangzhou Financial Holding Fund Management Co., LTD., Guangzhou Development Zone Industrial Fund Investment Group Co., LTD., and Guangzhou Guoju Venture Capital Investment Co., LTD., focusing on investment in the new generation of information technology, biomedicine and other fields. 

Introduction to Industrial Investors

Mingde Biotechnology Co., LTD. : Wuhan Mingde Biotechnology Co., Ltd. is mainly engaged in the research and development, production, sales and service of in vitro diagnostic reagents and diagnostic instruments, and is committed to becoming a leading enterprise providing innovative and leading medical service products for medical institutions. Company integration innovation, deep customer requirements, focusing on the critical areas, stretches out of body diagnostic testing, third party medical test, certification advisory services and medical information platform construction, and a series of integrated solutions, support the medical institutions to provide more real-time, accurate, the wisdom of medical services, so as to help patients enjoy more convenient and high quality medical and health services. After years of development, the company has developed into a leading in vitro diagnostic integrated solutions provider in China. In the future, the company will continue to take "innovation and timely diagnosis, leading smart medical care" as its mission, adhere to the core values of "customer-centered, striver oriented, embrace change, continuous learning and growth", and continue to build a service loop centered on people's medical and health service needs.